par
Barbara Kram, Editor | April 03, 2006
Influenza viruses mutate frequently. Some mutations confer drug resistance to influenza viruses. Repeated and improper use of anti-influenza drugs could allow resistant influenza viruses to flourish.
Interested parties may submit comments on this final rule by May 22, 2006. Comments may be submitted electronically through the Federal eRulemaking Portal: www.regulations.gov or to the Agency Web site: www.fda.gov/dockets/ecomments. Written comments may be faxed to 301-827-6870, or delivered by mail or hand to: Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Room 1061, Rockville, MD 20852. All comments must be identified by Docket No: 2006N-0106. The order of prohibition will become effective June 20, 2006, unless FDA revokes the order, modifies it, or extends the comment period.
Ad Statistics
Times Displayed: 19572
Times Visited: 365 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
Additional information on the final rule may be found in the March 22, 2006 Federal Register or by contacting Kim Young, Center for Veterinary Medicine (HFV-230), Food and Drug Administration, 7519 Standish Place, Rockville, MD 20855, 240-276-9207, e-mail: kim.young@fda.hhs.gov
Information about the pandemic flu may be found at: www.pandemicflu.gov.
Back to HCB News
